132 results
P
SA+ patients, SA- patients, healthy controls
I/C
blood biomarkers, immune, inflammatory, and neurotoxic profiles, meta-analysis, SA+ vs. healthy controls, SA+ vs. SA-, current vs. lifetime SA
O
increased immune activation, inflammation, neurotoxicity, lowered neuroprotection, risk of SA
P
individuals with pre-existing sleep apnea (SA), individuals without SA, 25,062 SA cases, 313,372 controls, 20,582 glaucoma cases, 119,318 controls
I/C
genetic data, two-sample Mendelian randomization (MR) analyses, genome-wide association study (GWAS), inverse variance weighted regression of genetic susceptibility for SA on risk of glaucoma, genetically predicted SA and glaucoma susceptibility
O
association between SA and glaucoma, risk of glaucoma
P
patients with de novo IAs
I/C
systematic review and meta-analysis of existing de novo IA cohorts, initial IAs in the middle cerebral artery
O
de novo IAs
P
idosos
I/C
prevenção de quedas, não-prevenção
O
prevenção de quedas
P
NAFLD, elderly, pre-LT type II diabetes mellitus
I/C
de novo PTMS, other liver diseases
O
cardiovascular disease events
P
pacientes con COVID-19
I/C
inhibidores de la enzima convertidora de angiotensina, bloqueadores del receptor de angiotensina II, placebo o ningún tratamiento
O
efectos sobre la COVID-19
P
patients with de novo coronary artery lesions
I/C
drug-coated balloon (DCB) treatment, non-DCB devices (such as plain old balloon angioplasty (POBA), bare-metal stents (BMS), or drug-eluting stents (DES))
O
target lesion revascularization (TLR)
P
mujeres postmenopáusicas
I/C
uso de estrógenos
O
infección del tracto urinario sintomática
P
patients with atrial fibrillation (AF)
I/C
catheter ablation (CA), surgical ablation (SA)
O
absence of AF during a 12-month follow-up period without the use of antiarrhythmic drugs
P
advanced gastric cancer patients
I/C
neoadjuvant chemotherapy followed by surgery (NACS), surgery alone (SA)
O
overall survival, perioperative indicators, post-operative complications